Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22031522 | 0.85 | RET (0.55) | RET | |
| SCHEMBL23618974 | 0.84 | RET (0.62) | RET | |
| SCHEMBL30557676 | 0.83 | RET (0.51) | RET | |
| SCHEMBL22909674 | 0.83 | RET (0.57) | RET | |
| SCHEMBL31590149 | 0.82 | RET (0.57) | RET | |
| SCHEMBL29483272 | 0.81 | RET (0.57) | RET | |
| SCHEMBL29629368 | 0.81 | RET (0.57) | RET | |
| SCHEMBL1907280 | 0.81 | RET (0.56) | RET | |
| SCHEMBL29341087 | 0.81 | RET (0.56) | RET | |
| SCHEMBL29629359 | 0.80 | RET (0.56) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865952-A | RET selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-114072404-B | RET selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20220289740-A1 | RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shouyao Holdings (beijing) Co., Ltd. (CN) | 2022-09-15 | — | — | US | disclosed |
| EP-3998265-A1 | RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| EP-3998265-A1 | RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| WO-2021008455-A1 | RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 首药控股(北京)有限公司 | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289740-A1 | RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | RET, REN, ROR1 | RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.